Detection of a distinctive genomic signature in rhabdoid glioblastoma, A Rare disease entity identified by whole exome sequencing and whole transcriptome sequencing

Translational Oncology

Volumn 8, Issue 4, 2015, Pages 279-287

  Koh, Youngil ^a,c   Park, Inho ^b   Sun, Chung Hyun ^b   Lee, Seungmook ^b   Yun, Hongseok ^b   Park, Chul Kee ^a,c   Park, Sung Hye ^a,c   Park, Joo Kyung ^a   Lee, Se Hoon ^a,c  

^a Seoul National University Hospital   (South Korea)

^b Bioinformatics Group   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL MEMBRANE ANTIGEN; GLIAL FIBRILLARY ACIDIC PROTEIN; INI 1 PROTEIN; KI 67 ANTIGEN; MLL3 PROTEIN; NOTCH1 RECEPTOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN; SCATTER FACTOR RECEPTOR; TEMOZOLOMIDE; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ADULT; ARTICLE; CASE REPORT; CRANIOTOMY; DOWN REGULATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE FREQUENCY; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GLIOBLASTOMA; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RHABDOID TUMOR; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR RECURRENCE; UPREGULATION; WHOLE EXOME SEQUENCING; WHOLE TRANSCRIPTOME SEQUENCING; YOUNG ADULT;

EID: 84940197086     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2015.05.003     Document Type: Article

References (37)

1. Mutou J, Hirose Y, Ikeda E, Yoshida K, Nakazato Y, and Kawase T (2011). Malignant brain tumor with rhabdoid features in an adult. Neurol Med Chir 51, 449–454.
2. Momota H, Iwami K, Fujii M, Motomura K, and Natsume A, et al (2011). Rhabdoid glioblastoma in a child: case report and literature review. Brain Tumor Pathol 28, 65–70.
3. Wyatt-Ashmead J, Kleinschmidt-DeMasters BK, Hill DA, Mierau GW, and McGavran L, et al (2001). Rhabdoid glioblastoma. Clin Neuropathol 20, 248–255.
4. Lath R, Unosson D, Blumbergs P, Stahl J, and Brophy BP (2003). Rhabdoid glioblastoma: a case report. J Clin Neurosci 10, 325–328.
5. He MX and Wang JJ (2011). Rhabdoid glioblastoma: case report and literature review. Neuropathology 31, 421–426.
6. Fung KM, Perry A, Payner TD, and Shan Y (2004). Rhabdoid glioblastoma in an adult. Pathology 36, 585–587.
7. Endo S, Terasaka S, Yamaguchi S, Ikeda H, and Kato T, et al (2013). Primary rhabdoid tumor with low grade glioma component of the central nervous system in a young adult. Neuropathology 33, 185–191.
8. Kleinschmidt-DeMasters BK, Alassiri AH, Birks DK, Newell KL, Moore W, and Lillehei KO (2010). Epithelioid versus rhabdoid glioblastomas are distinguished by monosomy 22 and immunohistochemical expression of INI-1 but not claudin 6. Am J Surg Pathol 34, 341–354.
9. Babu R, Hatef J, McLendon RE, Cummings TJ, and Sampson JH, et al (2013). Clinicopathological characteristics and treatment of rhabdoid glioblastoma. J Neurosurg 119, 412–419.
10. Hiroyuki M, Ogino J, Takahashi A, Hasegawa T, and Wakabayashi T (2015). Rhabdoid glioblastoma: an aggressive variaty of astrocytic tumor. Nagoya J Med Sci 77, 321–328.
11. Kleinschmidt-DeMasters BK, Aisner DL, Birks DK, and Foreman NK (2013). Epithelioid GBMs show a high percentage of BRAF V600E mutation. Am J Surg Pathol 37, 685–698.
12. Lee RS, Stewart C, Carter SL, Ambrogio L, and Cibulskis K, et al (2012). A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest 122, 2983–2988.
13. Hasselblatt M, Isken S, Linge A, Eikmeier K, and Jeibmann A, et al (2013). High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors. Genes Chromosomes Cancer 52, 185–190.
14. Louis DN (2007). International Agency for Research on Cancer. WHO classification of tumours of the central nervous system. Lyon: International Agency for Research on Cancer; 2007 [309 p. pp.].
15. Li H and Durbin R (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760.
16. McKenna A, Hanna M, Banks E, Sivachenko A, and Cibulskis K, et al (2010). The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20, 1297–1303.
17. Cingolani P, Platts A, Wang le L, Coon M, and Nguyen T, et al (2012). A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly 6, 80–92.
18. Huillard E, Hashizume R, Phillips JJ, Griveau A, and Ihrie RA, et al (2012). Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A 109, 8710–8715.
19. McPherson A, Hormozdiari F, Zayed A, Giuliany R, and Ha G, et al (2011). deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 7, e1001138.
20. Chen K, Wallis JW, Kandoth C, Kalicki-Veizer JM, and Mungall KL, et al (2012). BreakFusion: targeted assembly-based identification of gene fusions in whole transcriptome paired-end sequencing data. Bioinformatics 28, 1923–1924.
21. Iyer MK, Chinnaiyan AM, and Maher CA (2011). ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 27, 2903–2904.
22. Mortazavi A, Williams BA, McCue K, Schaeffer L, and Wold B (2008). Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5, 621–628.
23. Shugay M, Ortiz de Mendibil I, Vizmanos JL, and Novo FJ (2013). Oncofuse: a computational framework for the prediction of the oncogenic potential of gene fusions. Bioinformatics 29, 2539–2546.
24. Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, and Rye IH, et al (2010). Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A 107, 16910–16915.
25. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, and Kinzler KW (2013). Cancer genome landscapes. Science 339, 1546–1558.
26. Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, and Collins VP, et al (2013). Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A 110, 4009–4014.
27. Kita D, Yonekawa Y, Weller M, and Ohgaki H (2007). PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol 113, 295–302.
28. Fuller GN and Scheithauer BW (2007). The 2007 Revised World Health Organization (WHO) Classification of Tumours of the Central Nervous System: newly codified entities. Brain Pathol 17, 304–307.
29. Byeon SJ, Cho HJ, Baek HW, Park CK, and Choi SH, et al (2014). Rhabdoid glioblastoma is distinguishable from classical glioblastoma by cytogenetics and molecular genetics. Hum Pathol 45, 611–620.
30. Fassl A, Tagscherer KE, Richter J, Berriel Diaz M, and Alcantara Llaguno SR, et al (2012). Notch1 signaling promotes survival of glioblastoma cells via EGFR-mediated induction of anti-apoptotic Mcl-1. Oncogene 31, 4698–4708.
31. Natarajan S, Li Y, Miller EE, Shih DJ, and Taylor MD, et al (2013). Notch1-induced brain tumor models the sonic hedgehog subgroup of human medulloblastoma. Cancer Res 73, 5381–5390.
32. Ehrman LA, Mu X, Waclaw RR, Yoshida Y, and Vorhees CV, et al (2013). The LIM homeobox gene Isl1 is required for the correct development of the striatonigral pathway in the mouse. Proc Natl Acad Sci U S A 110, E4026-4035.
33. Agaimy A, Erlenbach-Wunsch K, Konukiewitz B, Schmitt AM, and Rieker RJ, et al (2013). ISL1 expression is not restricted to pancreatic well-differentiated neuroendocrine neoplasms, but is also commonly found in well and poorly differentiated neuroendocrine neoplasms of extrapancreatic origin. Mod Pathol 26, 995–1003.
34. Deng Y, Yao L, Chau L, Ng SS, and Peng Y, et al (2003). N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer 106, 342–347.
35. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, and Ambros P, et al (1998). Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 394, 203–206.
36. Roberts CW, Leroux MM, Fleming MD, and Orkin SH (2002). Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5. Cancer Cell 2, 415–425.
37. Knutson SK, Warholic NM, Wigle TJ, Klaus CR, and Allain CJ, et al (2013). Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci U S A 110, 7922–7927.